

350 **Supplemental Tables**

351 A)

History of Malaria	Residence in a Malaria-endemic Country ¹	Travel to a Malaria-endemic Area
3-year deferral for any donor who has a history of malaria ²	3-year deferral for any donor with a history of residence in a malaria-endemic country	1-year deferral after last departure from a malaria-endemic area, whether or not donor reports prophylaxis use 3-year deferral for any donor who previously resided in an endemic area and now resides in a non-endemic area for less than 3 consecutive years <ul style="list-style-type: none"> ○ If donor has resided in a non-endemic area for more than three consecutive years, then follow 1-year deferral
Must remain symptom free and reside in a non-endemic area during deferral period		

352 ¹Residency is defined as a continuous stay of longer than 5 years in a country.

353 ²Donor is considered eligible if they remain free of malaria symptoms for 3-years while residing in a non-endemic country
 354 and meets all other eligibility criteria

355 B)

Remaining blood product components from donors under investigation:
Quarantine undistributed cellular and acellular (i.e. fresh frozen plasma) blood components
Notify consignees to retrieve and quarantine distributed cellular blood components <ul style="list-style-type: none"> ○ If donor deferred because of history of malaria, and components have been transfused, encourage consignees to notify recipient’s physician regarding need to monitor patient for possible malaria infection for 3 months post-transfusion
No recommendation to notify consignees of distributed acellular products

366 Supplemental Table 1. A) FDA Guidance for Industry¹³, recommendations for the deferral of donors currently residing in
 367 non-endemic areas related to malaria exposure risk and B) quarantine of components under investigation

Donor	Co-Component	Distributed to Consignee	Requires Quarantine
A	Recovered Plasma	No	No
B	Recovered Plasma	No	No
C	Fresh Frozen Plasma	Yes	No
D	Fresh Frozen Plasma	Yes	No
E	Recovered Plasma	No	No
F	Recovered Plasma	No	No
G	Cryoprecipitate	Yes	No
H	Leukocyte Reduced Red Blood Cells	Yes	Yes

368

369 Supplemental Table 2. Additional donated product co-components by donors under investigation. Donor H contributed
370 blood products requiring quarantine, but the components were transfused prior to the start of the investigation.

371

372

373

374

375